Literature DB >> 19572188

Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.

Paul G Baverel1, Radojka M Savic, Justin J Wilkins, Mats O Karlsson.   

Abstract

The aim of the study was to evaluate the nonparametric estimation methods available in NONMEM VI in comparison with the parametric first-order method (FO) and the first-order conditional estimation method (FOCE) when applied to real datasets. Four methods for estimating model parameters and parameter distributions (FO, FOCE, nonparametric preceded by FO (FO-NONP) and nonparametric preceded by FOCE (FOCE-NONP)) were compared for 25 models previously developed using real data and a parametric method. Numerical predictive checks were used to test the appropriateness of each model. Up to 1000 new datasets were simulated from each model and with each method to construct 90% and 50% prediction intervals. The mean absolute error and the mean error of the different outcomes investigated were computed as indicators of imprecision and bias respectively and formal statistical tests were performed. Overall, less imprecision and less bias were observed with nonparametric methods than with parametric methods. Across the 25 models, t-tests revealed that imprecision and bias were significantly lower (P < 0.05) with FOCE-NONP than with FOCE for half of the NPC outcomes investigated. Improvements were even more pronounced with FO-NONP in comparison with FO. In conclusion, when applied to real datasets and evaluated by numerical predictive checks, the nonparametric estimation methods in NONMEM VI performed better than the corresponding parametric methods (FO or FOCE).

Mesh:

Year:  2009        PMID: 19572188     DOI: 10.1007/s10928-009-9122-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  28 in total

1.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

2.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

3.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Authors:  Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-26       Impact factor: 2.745

5.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

6.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

7.  Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.

Authors:  Bengt Hamrén; Hans Ericsson; Ola Samuelsson; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

8.  Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.

Authors:  R Bruno; M C Iliadis; B Lacarelle; V Cosson; J W Mandema; Y Le Roux; G Montay; A Durand; M Ballereau; M Alasia
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

9.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

10.  Application of population pharmacokinetics to cladribine.

Authors:  Synnöve Lindemalm; Radojka M Savic; Mats O Karlsson; Gunnar Juliusson; Jan Liliemark; Freidoun Albertioni
Journal:  BMC Pharmacol       Date:  2005-03-09
View more
  4 in total

1.  Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.

Authors:  Paul G Baverel; Radojka M Savic; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-13       Impact factor: 2.745

2.  Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants.

Authors:  Michael Cohen-Wolkowiez; Daniele Ouellet; P Brian Smith; Laura P James; Ashley Ross; Janice E Sullivan; Michele C Walsh; Arlene Zadell; Nancy Newman; Nicole R White; Angela D M Kashuba; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

3.  Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate.

Authors:  Femke de Velde; Brenda C M de Winter; Michael N Neely; Walter M Yamada; Birgit C P Koch; Stephan Harbarth; Elodie von Dach; Teun van Gelder; Angela Huttner; Johan W Mouton
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

4.  Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients.

Authors:  Femke de Velde; Brenda C M de Winter; Michael N Neely; Jan Strojil; Walter M Yamada; Stephan Harbarth; Angela Huttner; Teun van Gelder; Birgit C P Koch; Anouk E Muller
Journal:  Pharmaceutics       Date:  2021-12-16       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.